C. Compton

First name
C.
Last name
Compton
Czira, A., Banks, V., Requena, G., Wood, R., Tritton, T., Wild, R., et al. (2024). Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B(2)-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study. Bmj Open, 14, e072361. http://doi.org/10.1136/bmjopen-2023-072361
View
Rothnie, K. J., Numbere, B., Gelwicks, S., Lu, Y., Sharma, R., Compton, C., et al. (2023). Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK. Int J Chron Obstruct Pulmon Dis, 18, 2673-2685. http://doi.org/10.2147/copd.s413947
View
Ismaila, A. S., Rothnie, K. J., Wood, R. P., Banks, V. L., Camidge, L. J., Czira, A., et al. (2023). Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respir Res, 24, 229. http://doi.org/10.1186/s12931-023-02523-1
View
Requena, G., Czira, A., Banks, V., Wood, R., Tritton, T., Castillo, C., et al. (2023). Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England. Int J Chron Obstruct Pulmon Dis, 18, 2039-2054. http://doi.org/10.2147/copd.s408688
View
Requena, G., Czira, A., Banks, V., Wood, R., Tritton, T., Castillo, C. M., et al. (2023). Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England. Int J Chron Obstruct Pulmon Dis, 18, 1431-1444. http://doi.org/10.2147/copd.s411437
View
Czira, A., Requena, G., Banks, V., Wood, R., Tritton, T., Castillo, C. M., et al. (2023). Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 18, 643-659. http://doi.org/10.2147/copd.s405498
View
Requena, G., Banks, V., Czira, A., Wood, R., Tritton, T., Wild, R., et al. (2023). Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. Int J Chron Obstruct Pulmon Dis, 18, 231-245. http://doi.org/10.2147/copd.s389281
View
Halpin, D. M. G., Rothnie, K. J., Banks, V., Czira, A., Compton, C., Wood, R., et al. (2022). Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int J Chron Obstruct Pulmon Dis, 17, 2417-2429. http://doi.org/10.2147/copd.s370540
View
Czira, A., Banks, V., Requena, G., Wood, R., Tritton, T., Wild, R., et al. (2022). Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England. Bmj Open Respir Res, 9. http://doi.org/10.1136/bmjresp-2022-001243
View
Requena, G., Banks, V., Czira, A., Wood, R., Tritton, T., Wild, R., et al. (2022). Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 17, 1781-1795. http://doi.org/10.2147/copd.s365480
View